$276 Million is the total value of venBio Partners LLC's 7 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | ACELYRIN INC | $80,616,107 | – | 3,857,230 | +100.0% | 29.18% | – | |
| ALXO | ALX ONCOLOGY HLDGS INC | $72,846,437 | +66.2% | 9,699,925 | 0.0% | 26.36% | +8.5% | |
| PHVS | Buy | PHARVARIS N V | $64,567,134 | +251.8% | 4,264,672 | +87.2% | 23.37% | +129.7% |
| HRMY | HARMONY BIOSCIENCES HLDGS IN | $36,435,585 | +7.8% | 1,035,396 | 0.0% | 13.19% | -29.6% | |
| Sell | VENTYX BIOSCIENCES INC | $13,908,250 | -81.9% | 424,032 | -81.6% | 5.03% | -88.2% | |
| ELEV | Buy | ELEVATION ONCOLOGY INC | $4,429,668 | +24.9% | 2,914,255 | +56.1% | 1.60% | -18.4% |
| IMPL | IMPEL PHARMACEUTICALS INC | $3,504,935 | -9.3% | 2,759,791 | 0.0% | 1.27% | -40.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERONA PHARMA PLC | 15 | Q2 2022 | 22.2% |
| AKERO THERAPEUTICS INC | 14 | Q3 2022 | 65.3% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 73.8% |
| HARMONY BIOSCIENCES HLDGS IN | 13 | Q3 2023 | 21.1% |
| APELLIS PHARMACEUTICALS INC | 11 | Q2 2021 | 62.0% |
| PHARVARIS N V | 11 | Q3 2023 | 25.2% |
| IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.3% |
| ELEVATION ONCOLOGY INC | 10 | Q3 2023 | 4.2% |
| VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 42.7% |
| PRECISION BIOSCIENCES INC | 7 | Q3 2020 | 62.0% |
View venBio Partners LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View venBio Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.